Pharmacyclics Inc. (PCYC) announced Wednesday morning that it has submitted a New Drug Application to the FDA for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.
Pharmacyclics gapped up Wednesday and climbed sharply during the first hour of trade. The stock ended the day with a gain of 10.74 at $100.26 on above average volume. Pharmacyclics surged past resistance and set a new high for the year.
by RTT Staff Writer
For comments and feedback: email@example.com